The proinflammatory cytokines IL-1β and TNF-α induce the expression of Synoviolin, an E3 ubiquitin ligase, in mouse synovial fibroblasts via the Erk1/2-ETS1 pathway

Arthritis Research and Therapy

Volumn 8, Issue 6, 2006, Pages

  Gao, Beixue ^a   Calhoun, Karen ^a   Fang, Deyu ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETS1 PROTEIN, MOUSE; HRD1 PROTEIN, MOUSE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR ETS 1; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE;

ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CYTOLOGY; DBA MOUSE; EXPERIMENTAL ARTHRITIS; FEEDBACK SYSTEM; FIBROBLAST; METABOLISM; MOUSE; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNOVIUM; WESTERN BLOTTING;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEEDBACK, PHYSIOLOGICAL; FIBROBLASTS; INTERLEUKIN-1BETA; MICE; MICE, INBRED DBA; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEIN C-ETS-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES;

EID: 67651142330     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2081     Document Type: Article

References (37)

1. Chen V, Croft D, Purkis P, Kramer IM: Co-culture of synovial fibroblasts and differentiated U937 cells is sufficient for high interleukin-6 but not interleukin-1beta or tumour necrosis factor-alpha release. Br J Rheumatol 1998, 37:148-156.
2. Cunnane G, Warnock M, Fye KH, Daikh DI: Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002, 47:445-449.
3. Komuro H, Olee T, Kuhn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M: The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum 2001, 44 2768-2776.
4. Takayanagi H, Ogasawara K, Hida S, Chiba T, Murata S, Sato K, Takaoka A, Yokochi T, Oda H, Tanaka K, et al.: T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000, 408:600-605.
5. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, et al.: Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004, 10:617-624.
6. Hampton RY, Gardner RG, Rine J: Role of 26S proteasome and HRD genes in the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase, an integral endoplasmic reticulum membrane protein. Mol Biol Cell 1996, 7:2029-2044.
7. Gardner RG, Swarbrick GM, Bays NW, Cronin SR, Wilhovsky S, Seelig L, Kim C, Hampton RY: Endoplasmic reticulum degradation requires lumen to cytosol signaling. Transmembrane control of Hrd1p by Hrd3p. J Cell Biol 2000, 151:69-82.
8. Kikkert M, Doolman R, Dai M, Avner R, Hassink G, van Voorden S, Thanedar S, Roitelman J, Chau V, Wiertz E: Human HRD1 is an E3 ubiquitin ligase involved in degradation of proteins from the endoplasmic reticulum. J Biol Chem 2004, 279:3525-3534.
9. Bays NW, Gardner RG, Seelig LP, Joazeiro CA, Hampton RY: Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation. Nat Cell Biol 2001, 3:24-29.
10. Yagishita N, Ohneda K, Amano T, Yamasaki S, Sugiura A, Tsuchimochi K, Shin H, Kawahara K, Ohneda O, Ohta T, et al.: Essential role of synoviolin in embryogenesis. J Biol Chem 2005, 280 7909-7916.
11. Amano T, Yamasaki S, Yagishita N, Tsuchimochi K, Shin H, Kawahara K, Aratani S, Fujita H, Zhang L, Ikeda R, et al.: Synoviolin/ Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy. Genes Dev 2003, 17:2436-2449.
12. Yamasaki S, Yagishita N, Tsuchimochi K, Nishioka K, Nakajima T: Rheumatoid arthritis as a hyper-endoplasmic reticulum-associated degradation disease. Arthritis Res Ther 2005, 7:181-186.
13. Kelemen BR, Hsiao K, Goueli SA: Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chemi 2002, 277:8741-8748.
14. Barr RK, Kendrick TS, Bogoyevitch MA: Identification of the critical features of a small peptide inhibitor of JNK activity. J Biol Chem 2002, 277:10987-10997.
15. de Laszlo SE, Visco D, Agarwal L, Chang L, Chin J, Croft G, Forsyth A, Fletcher D, Frantz B, Hacker C, et al.: Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg Med Chem Lett 1998, 8:2689-2694.
16. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J: Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995, 270:14255-14258.
17. Gouze JN, Stoddart MJ, Gouze E, Palmer GD, Ghivizzani SC, Grodzinsky AJ, Evans CH: In vitro gene transfer to chondrocytes and synovial fibroblasts by adenoviral vectors. Methods Mol Med 2004, 100 147-164.
18. Fang D, Elly C, Gao B, Fang N, Altman Y, Joazeiro C, Hunter T, Copeland N, Jenkins N, Liu YC: Dysregulation of T lymphocyte function in itchy mice: A role for Itch in TH2 differentiation. Nat Immunol 2002, 3:281-287.
19. Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE: Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003, 93 321-329.
20. Gortz B, Hayer S, Tuerck B, Zwerina J, Smolen JS, Schett G: Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. Arthritis Res Ther 2005, 7:R1140-R1147.
21. Hammaker DR, Boyle DL, Chabaud-Riou M, Firestein GS: Regulation of c-Jun N-terminal kinase by MEKK-2 and mitogen-activated protein kinase kinase kinases in rheumatoid arthritis. J Immunol 2004, 172 1612-1618.
22. Lu H, Sun T, Yao L, Zhang Y: Role of protein tyrosine kinase in IL-1 beta induced activation of mitogen-activated protein kinase in fibroblast-like synoviocytes of rheumatoid arthritis. Chin Med J (Engl) 2000, 113:872-876.
23. Toh ML, Yang Y, Leech M, Santos L, Morand EF: Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of the mitogen-activated protein kinases, in rheuma-toid arthritis: up-regulation by interleukin-1beta and glucocorticoids. Arthritis Rheum 2004, 50:3118-3128.
24. Vergne-Salle P, Leger DY, Bertin P, Treves R, Beneytout JL, Liagre B: Effects of the active metabolite of leflunomide, A77 1716, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine 2005, 31:335-348.
25. Gao M, Labuda T, Xia Y, Gallagher E, Fang D, Liu YC, Karin M: Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 2004, 306:271-275.
26. Krasnow SW, Zhang LQ, Leung KY, Osborn L, Kunkel S, Nabel GJ: Tumor necrosis factor-alpha, interleukin 1, and phorbol myristate acetate are independent activators of NF-kappa B which differentially activate T cells. Cytokine 1991, 3:372-379.
27. Redlich K, Kiener HP, Schett G, Tohidast-Akrad M, Selzer E, Radda I, Stummvoll GH, Steiner CW, Groger M, Bitzan P, et al.: Overexpression of transcription factor ETS1 in rheumatoid arthritis synovial membrane: Regulation of expression and activation by interleukin-1 and tumor necrosis factor alpha. Arthritis Rheum 2001, 44:266-274.
28. Tsuchimochi K, Yagishita N, Yamasaki S, Amano T, Kato Y, Kawahara K, Aratani S, Fujita H, Ji F, Sugiura A, et al.: Identification of a crucial site for synoviolin expression. Mol Cell Biol 2005, 25:7344-7356.
29. Pourtier-Manzanedo A, Vercamer C, Van Belle E, Mattot V, Mouquet F, Vandenbunder B: Expression of an ETS1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model. Oncogene 2003, 22:1795-1806.
30. Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K: Matrix metalloproteinase-1 up-regulation by hepatocyte growth factor in human dermal fibroblasts via ERK signaling pathway involves Ets1 and Fli1. Nucleic Acids Res 2005, 33:3540-3549.
31. Strand V, Kavanaugh AF: The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford) 2004, 43(Suppl 3):iIi10-iii16.
32. Isomaki P, Punnonen J: Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 1997, 29:499-507.
33. Firestein GS, Manning AM: Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum 1999, 42 609-621.
34. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, Mapp PI, Morris CJ, Blake DR, Kaltschmidt C, Baeuerle PA: Activation of the transcription factor nuclear factor-kappaB in human inflamed synovial tissue. Arthritis Rheum 1996, 39:583-591.
35. Han Z, Boyle DL, Aupperle KR, Bennett B, Manning AM, Firestein GS: Jun N-terminal kinase in rheumatoid arthritis. J Pharmacol Exp Ther 1999, 291:124-130.
36. Sharrocks AD: The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001, 2:827-837.
37. Ito H, Duxbury M, Benoit E, Clancy TE, Zinner MJ, Ashley SW, Whang EE: Prostaglandin E2 enhances pancreatic cancer invasiveness through an ETS1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004, 64:7439-7446.